Luciolap（lynparza）Olaparib 50mg online

Luciolap（lynparza）is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
Ovarian cancer
1.for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
2.for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Luciolap.
Breast cancer
in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Luciolap.
DOSAGE AND ADMINISTRATION
1.To avoid substitution errors and overdose, do not substitute Luciolap tablets with Luciolap capsules on a milligram-to-milligram basis due to differences in the dosingand bioavailability of each formulation.
2.Recommended tablet dose is 300 mg taken orally twice daily with or without food.
3.Continue treatment until disease progression or unacceptable toxicity.
4.For adverse reactions, consider dose interruption or dose reduction.
5.For moderate renal impairment (CLcr 31-50 mL/min), reduce dose to 200 mg twice daily.
Luciolap’s brand name is lynparza® by AstraZeneca. Luciolap is a generic oncologic prescription medicine from Lucuis, which is the biggest pharmaceutical company in Bangladesh.
For more Prescribing information，please check the → “FDA Prescribing Information”.